6-43770795-G-A

Variant summary

Our verdict is Likely benign. The variant received -6 ACMG points: 0P and 6B. BP4_ModerateBS2

The NM_003376.6(VEGFA):​c.89G>A​(p.Arg30His) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000646 in 1,486,918 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. 11/19 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).

Frequency

Genomes: 𝑓 0.000066 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000064 ( 1 hom. )

Consequence

VEGFA
NM_003376.6 missense

Scores

1
4
12

Clinical Significance

Uncertain significance criteria provided, single submitter U:1

Conservation

PhyloP100: 2.01

Publications

4 publications found
Variant links:
Genes affected
VEGFA (HGNC:12680): (vascular endothelial growth factor A) This gene is a member of the PDGF/VEGF growth factor family. It encodes a heparin-binding protein, which exists as a disulfide-linked homodimer. This growth factor induces proliferation and migration of vascular endothelial cells, and is essential for both physiological and pathological angiogenesis. Disruption of this gene in mice resulted in abnormal embryonic blood vessel formation. This gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Elevated levels of this protein are found in patients with POEMS syndrome, also known as Crow-Fukase syndrome. Allelic variants of this gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. Alternatively spliced transcript variants encoding different isoforms have been described. There is also evidence for alternative translation initiation from upstream non-AUG (CUG) codons resulting in additional isoforms. A recent study showed that a C-terminally extended isoform is produced by use of an alternative in-frame translation termination codon via a stop codon readthrough mechanism, and that this isoform is antiangiogenic. Expression of some isoforms derived from the AUG start codon is regulated by a small upstream open reading frame, which is located within an internal ribosome entry site. The levels of VEGF are increased during infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), thus promoting inflammation by facilitating recruitment of inflammatory cells, and by increasing the level of angiopoietin II (Ang II), one of two products of the SARS-CoV-2 binding target, angiotensin-converting enzyme 2 (ACE2). In turn, Ang II facilitates the elevation of VEGF, thus forming a vicious cycle in the release of inflammatory cytokines. [provided by RefSeq, Jun 2020]

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Likely_benign. The variant received -6 ACMG points.

BP4
Computational evidence support a benign effect (MetaRNN=0.10343233).
BS2
High AC in GnomAd4 at 10 AD gene.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
VEGFANM_003376.6 linkc.89G>A p.Arg30His missense_variant Exon 1 of 8 ENST00000672860.3 NP_003367.4 P15692-13

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
VEGFAENST00000672860.3 linkc.89G>A p.Arg30His missense_variant Exon 1 of 8 NM_003376.6 ENSP00000500082.3 P15692-13A0A5F9ZH41

Frequencies

GnomAD3 genomes
AF:
0.0000657
AC:
10
AN:
152170
Hom.:
0
Cov.:
33
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.000147
Gnomad OTH
AF:
0.00
GnomAD2 exomes
AF:
0.000157
AC:
14
AN:
89130
AF XY:
0.000198
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.00
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.000358
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000644
AC:
86
AN:
1334748
Hom.:
1
Cov.:
35
AF XY:
0.0000760
AC XY:
50
AN XY:
658056
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
26490
American (AMR)
AF:
0.0000411
AC:
1
AN:
24346
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
22854
East Asian (EAS)
AF:
0.00
AC:
0
AN:
30302
South Asian (SAS)
AF:
0.0000280
AC:
2
AN:
71366
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
45758
Middle Eastern (MID)
AF:
0.000978
AC:
4
AN:
4090
European-Non Finnish (NFE)
AF:
0.0000702
AC:
74
AN:
1054614
Other (OTH)
AF:
0.0000910
AC:
5
AN:
54928
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.522
Heterozygous variant carriers
0
7
13
20
26
33
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000657
AC:
10
AN:
152170
Hom.:
0
Cov.:
33
AF XY:
0.0000807
AC XY:
6
AN XY:
74336
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41458
American (AMR)
AF:
0.00
AC:
0
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5174
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4836
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10616
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
314
European-Non Finnish (NFE)
AF:
0.000147
AC:
10
AN:
68024
Other (OTH)
AF:
0.00
AC:
0
AN:
2094
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.495
Heterozygous variant carriers
0
1
2
2
3
4
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.000330
Hom.:
0
Bravo
AF:
0.0000945
ExAC
AF:
0.0000447
AC:
3

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:1
Revision: criteria provided, single submitter
LINK: link

Submissions by phenotype

not specified Uncertain:1
Sep 16, 2021
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.89G>A (p.R30H) alteration is located in exon 1 (coding exon 1) of the VEGFA gene. This alteration results from a G to A substitution at nucleotide position 89, causing the arginine (R) at amino acid position 30 to be replaced by a histidine (H). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
-0.28
T
BayesDel_noAF
Benign
-0.34
CADD
Pathogenic
27
DANN
Uncertain
1.0
DEOGEN2
Benign
0.24
T;.;.;T;.;.;.;.;.;T;.;.;.;T;.
Eigen
Benign
0.054
Eigen_PC
Benign
0.057
FATHMM_MKL
Benign
0.76
D
LIST_S2
Uncertain
0.91
D;D;D;D;D;D;D;D;D;D;D;D;D;D;D
M_CAP
Benign
0.033
D
MetaRNN
Benign
0.10
T;T;T;T;T;T;T;T;T;T;T;T;T;T;T
MetaSVM
Benign
-1.1
T
PhyloP100
2.0
PrimateAI
Pathogenic
0.83
D
PROVEAN
Benign
-0.38
N;.;N;N;.;.;.;.;.;N;N;.;N;N;N
REVEL
Benign
0.092
Sift
Uncertain
0.0020
D;.;D;D;.;.;.;.;.;D;D;.;D;D;D
Sift4G
Uncertain
0.0080
D;.;D;D;D;D;.;D;.;D;D;D;D;D;D
Polyphen
1.0, 1.0, 0.99
.;.;.;.;D;D;.;D;D;.;.;.;.;.;.
MVP
0.39
ClinPred
0.29
T
GERP RS
1.9
PromoterAI
-0.0091
Neutral
RBP_binding_hub_radar
0.0
RBP_regulation_power_radar
1.7
gMVP
0.12
Mutation Taster
=297/3
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs780163839; hg19: chr6-43738532; API